Please use this identifier to cite or link to this item:
Title: Therapy in cerebrovascular disease: current status and future directions.
Austin Authors: Donnan, Geoffrey A 
Affiliation: Department of Neurology, Austin Hospital, Heidelberg, VIC.
Issue Date: 21-Oct-1991
Publication information: Medical Journal of Australia; 155(8): 563-71
Abstract: To assess the current status and future directions of therapy in cerebrovascular disease.English language literature search using MEDLINE, Index Medicus, reviews, texts and relevant papers.Information has been drawn from approximately 200 articles.Those articles with most relevance to current practice and future directions in the therapy of cerebrovascular disease have been cited.Much progress has been made over the last 30 years in the therapy of primary and secondary prevention of cerebrovascular disease. The introduction of antihypertensive agents has been largely responsible for the decline in mortality from stroke and, in some areas, the incidence. Anticoagulants such as warfarin protect against ischaemic stroke in patients with mitral or aortic valve disease and/or atrial fibrillation. Antiplatelet agents are clearly effective in the secondary prevention of ischaemic stroke after transient ischaemic attacks; the risk of stroke or death is reduced, on average, by 22%. In patients with subarachnoid haemorrhage, ischaemic complications caused by vasospasm are reduced by calcium channel blockers. A new wave of therapies is now on the horizon to minimise tissue damage in the early stages of ischaemic stroke ("tissue rescue") with the introduction of thrombolytic agents, calcium channel blockers, NMDA antagonists and haemodilution techniques and many of these are currently being subjected to clinical trial. If they prove to be effective, our current management of acute ischaemic stroke may alter dramatically.
Gov't Doc #: 1943940
Journal: Medical Journal of Australia
Type: Journal Article
Subjects: Age Factors
Anticoagulants.therapeutic use
Aspirin.therapeutic use
Cerebral Infarction.drug therapy.etiology
Cerebrovascular Disorders.drug therapy.prevention & control
Ischemic Attack, Transient.drug therapy.prevention & control
Platelet Aggregation Inhibitors.therapeutic use
Risk Factors
Subarachnoid Hemorrhage.drug therapy.prevention & control
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Dec 8, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.